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Glycated albumin is thought to more accurately reflect
glycemic control in diabetic hemodialysis patients than
hemoglobin A1c because of shortened red cell survival.
To test this, glycated hemoglobin and albumin levels were
measured in blood samples collected from 307 diabetic
subjects of whom 258 were on hemodialysis and 49 were
without overt renal disease. In diabetic subjects with renal
disease, relative to those without, the mean serum glucose
and glycated albumin concentrations were significantly
higher while hemoglobin A1c tended to be lower. The
glycated albumin to hemoglobin A1c ratio was significantly
increased in dialysis patients compared with the controls.
Hemoglobin A1c was positively associated with hemoglobin
and negatively associated with the erythropoietin dose in
hemodialysis patients, whereas these factors and serum
albumin did not significantly impact glycated albumin levels.
Using best-fit multivariate models, dialysis status significantly
impacted hemoglobin A1c levels without a significant effect
on glycated albumin. Our results show that in diabetic
hemodialysis patients, hemoglobin A1c levels significantly
underestimate glycemic control while those of glycated
albumin more accurately reflect this control.
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The vascular complications of diabetes mellitus,
including kidney disease, heart attack, and stroke are
increasing rapidly throughout the world.1 Diabetic nephro-
pathy now accounts for nearly 50% of incident dialysis
patients in the United States, and cardiovascular disease is the
leading cause of death.2 It is important to control conven-
tional atherosclerotic risk factors in diabetic dialysis patients,
including blood glucose, hypertension, hyperlipidemia, and
smoking to reduce cardiovascular disease events.
Several clinical tests are useful for measuring long-term
glycemic control in the general diabetic population. These
same tests are routinely performed in diabetic subjects with
chronic kidney disease and end-stage renal disease (ESRD);
however, their accuracy in these patients has not been
rigorously tested.3 Hemoglobin A1c (HbA1c), the most widely
used assay, measures the percentage of circulating hemoglobin
that has chemically reacted with glucose and reflects ambient
blood glucose control over the prior 120 days,
with the most profound effect in the preceding 30 days.3,4
Factors that shorten red blood cell (RBC) survival, including
severe nephropathy, may reduce HbA1c since the time
necessary for glucose to chemically bond with RBCs
decreases.5 If this significantly impacts HbA1c, dialysis patients
and clinicians would be falsely comforted by relatively low
HbA1c values despite high risk for subsequent cardiovascular
disease and infectious complications. Previous studies at-
tempting to address this concern were underpowered.6,7
Inaba et al.8 determined that HbA1c underestimated long-
term glycemic control in dialysis patients with diabetes, after
comparing the mean of random blood glucose concentra-
tions, HbA1c, and percentage of glycated albumin (% GA).
They found that the % GA assay provided a more accurate
assessment of glycemic control among Japanese hemodialysis
patients. The current study attempted to validate this
clinically important result and extend its application to
other ethnic groups.
RESULTS
Simultaneous blood samples were collected from 307 diabetic
patients, 258 were receiving chronic hemodialysis treatments
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and erythropoietin for advanced chronic kidney disease
(ESRD), and 49 were without kidney failure. Table 1 contains
demographic characteristics of the study population. All
patients with ESRD received erythropoietin, with mean
average (s.d.) weekly dose 22 876 (20 579) units. In all, 7%
(18/258) of dialysis patients and 0% of those without kidney
failure received a blood transfusion within the 90 days
preceding the study. Subjects without kidney failure had
mean serum creatinine concentration 1.0 (0.3) mg per 100 ml
and ESRD patients had mean urea reduction ratio 70.9
(8.8)%, Kt/V 1.5 (0.4), hemoglobin 11.8 (1.1) g per 100 ml,
transferrin saturation 25.4 (10.8)%, and ferritin 567 (424)
ng ml1. Overall, the mean (s.d.) serum glucose concentra-
tion in all participants was 168 (63) mg per 100 ml. The
nonnephropathy group had a mean (s.d.) serum glucose
concentration of 146 (66) mg per 100 ml and in ESRD
subjects 172 (62) mg per 100 ml. The coefficient of variation
was 100*(63/168) or 37.5%.
In ESRD patients, relative to those without kidney disease,
mean (s.d.) serum glucose concentrations were higher (172
(62) vs 146 mg per 100 ml (66); P¼ 0.024), % GA was higher
(18.7% (7.3), range: 7.7–52.7 vs 15.3% (5.5), range:
8.6–33.8%; Po0.0001), and HBA1c was lower (mean (s.d.),
range: 6.8% (1.6), 4.1–13.5 vs 7.3% (1.4), 5.1–11.3%;
P¼ 0.058) (Table 1). The % GA/HbA1c ratio was significantly
higher in ESRD patients relative to those without nephro-
pathy (2.72 (0.6) vs 2.07 (0.5); P¼ 0.0001). The % GA/HbA1c
ratio in diabetic subjects with ESRD compared with those
without kidney disease should approximate 1, if these assays
performed equally in both groups. Instead, the % GA/HbA1c
ratio in dialysis patients compared with subjects without
nephropathy was 1.31 (2.72/2.07).
Figure 1 displays the correlation between HbA1c and %
GA in hemodialysis patients and subjects without kidney
disease. A significant difference in the slope of the line
expressing this relationship among hemodialysis patients
(slope¼ 0.163) and subjects without nephropathy
(slope¼ 0.190) was observed (P¼ 0.0001). Figure 2 displays
HbA1c and % GA correlations with recent random blood
glucose measures. No significant differences in the relation-
ship between % GA and glucose concentrations were
observed between participants on hemodialysis and those
without kidney disease (P¼ 0.19), whereas marked differ-
ences were observed with HbA1c and glucose concentrations
(Po0.0001).
Table 2 contains the results of subgroup analyses. In
analyses restricted to African Americans, % GA/HbA1c ratios
were 2.77 in subjects with ESRD and 1.98 in those with
normal kidney function (P¼ 0.0001). Among non-African
Americans (predominantly Caucasians), the ratios were 2.62
in those with ESRD and 2.12 in those without kidney disease
Table 1 | Demographic and clinical characteristics of study
population
Variable
Diabetic ESRD
(N=258)
Diabetes, no
nephropathy
(N=49) P-value
Age, years 63.2 (12.0) 59.1 (13.8) 0.060
DM duration, years 19.1 (10.8) 11.8 (8.4) o0.0001
% male 53.1 40.8 0.115
% African American 63.6 32.7 o0.001
Height, inch 67.3 (4.0) 67.3 (3.8) 0.93
Weight, lb 189.7 (48.8) 237.3 (63.7) 0.007
% DM type 2 93.8 93.9 0.983
% ACEi/ARB 50.0 81.4 0.001
% current/former smokers 43.2 47.9 0.545
% transfused prior 90 days 7.0 0 0.089
Serum creatinine, mg per 100 ml NA 1.0 (0.3) —
Serum glucose, mg per 100 ml 172 (62) 146 (66) 0.024
Glycated albumin, g per 100 ml 0.69 (0.28) 0.62 (0.24) 0.071
Serum albumin, g per 100 ml 3.7 (0.4) 4.0 (0.6) 0.012
% glycated albumin 18.7 (7.3) 15.3 (5.5) 0.002
Hemoglobin, g per 100 ml 11.8 (1.1) 12.7 (1.8) 0.058
HbA1c, % 6.8 (1.6) 7.3 (1.4) 0.058
% GA/HbA1c 2.72 (0.6) 2.07 (0.5) 0.0001
Erythropoietin dose, U week1 22 876 (20 579) NA —
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
DM, diabetes mellitus; ESRD, end-stage renal disease; HbA1c, hemoglobin A1c; NA,
not applicable; % GA, percentage of glycated albumin.
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Figure 1 | Correlation between HbA1c and glycated albumin, by
ESRD status. Relationship between % HbA1c and % GA in diabetic
subjects with ESRD (upper panel) and without nephropathy (lower
panel). Slopes of the lines differ between groups (0.163 for diabetes
mellitus (DM)-ESRD, 0.190 for DM nonnephropathy patients,
P¼ 0.0001). Reference lines represent normal values.
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(P¼ 0.001). The % GA/HbA1c ratios were significantly
different in African American and non-African American
ESRD patients (P¼ 0.049) but not in African American and
non-African American subjects without nephropathy, respec-
tively. Relatively few African American subjects without
nephropathy were evaluated.
Multivariate linear regression was then performed to
determine which factors were associated with HbA1c
(Table 3). In a reduced best-fit model, serum glucose
concentration (Po0.0001), age (Po0.0001), and dialysis
status (Po0.0001) were all significant predictors of HbA1c. A
similar regression analysis was performed with % GA as the
outcome variable. In a reduced best-fit model, serum glucose
concentration (Po0.0001), age (P¼ 0.006), gender
(P¼ 0.002), ethnicity (P¼ 0.021), and diabetes duration
(P¼ 0.001) were significant predictors of % GA, while
dialysis status was not.
As the % GA/HbA1c ratio was significantly different in
patients with ESRD and those with normal kidney function, a
multivariate model adjusting for age, gender, ethnicity, and
diabetes duration was fit to control for those variables. This
model revealed similar results; as the % GA/HbA1c ratio
remained significantly different in diabetic subjects with
ESRD and without kidney disease (P¼ 0.003), with gender
(P¼ 0.003), serum glucose concentration (P¼ 0.001), ethni-
city (P¼ 0.048), and diabetes duration (P¼ 0.001) also
significantly related. Age was not associated (P¼ 0.41) with
this outcome.
Further analyses were conducted in diabetic subjects with
ESRD on hemodialysis. Figure 3 depicts the relationship
between HbA1c with both hemoglobin concentration and
erythropoietin dose. Hemoglobin concentration and HbA1c
were positively associated (P¼ 0.02); while erythropoietin
dose and HbA1c were negatively associated (P¼ 0.04).
Figure 4 reveals that the % GA was not significantly
associated with serum albumin, hemoglobin concentration,
or dose of erythropoietin.
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Figure 2 | Correlation between HbA1c and glycated albumin
assays with random serum glucose concentrations, by ESRD
status. Upper panel: HbA1c vs mean serum glucose concentration;
when testing the regression lines there is a significant difference
between diabetic hemodialysis patients and those without
nephropathy, Po0.0001. Lower panel: % GA vs mean serum glucose
concentration; testing the regression lines there is no significant
difference between the groups, P¼ 0.19. Circles depict subjects
without nephropathy; boxes depict dialysis patients.
Table 2 | Subgroup comparisons, by ethnicity and affection status
Ethnicity Group N GA, % HbA1c, % Ratio
African American DM-ESRD 164 19.3±7.5 6.9±1.6 2.77±0.66
African American DM no nephropathy 16 13.9±3.7 7.0±1.2 1.98±0.40
P-value 0.0007 0.80 0.0001
Non-African American DM-ESRD 94 17.7±6.8 6.7±1.5 2.61±0.59
Non-African American DM no nephropathy 33 16.0±6.1 7.4±1.5 2.12±0.52
P-value 0.21 0.01 0.001
Group Ethnicity N GA, % HbA1c, % Ratio
DM-ESRD African American 164 19.3±7.5 6.9±1.6 2.77±0.66
DM-ESRD Non-African American 94 17.7±6.8 6.7±1.5 2.61±0.59
P-value 0.083 0.27 0.049
DM no nephropathy African American 16 13.9±3.7 7.0±1.2 1.98±0.40
DM no nephropathy Non-African American 33 16.0±6.1 7.4±1.5 2.12±0.52
P-value 0.30 0.32 0.42
DM, diabetes mellitus; ESRD, end-stage renal disease; GA, glycated albumin; HbA1c, hemoglobin A1c.
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Finally, a best-fit multivariate model was constructed for
hemodialysis patients including all laboratory parameters
(data not shown). Predictors of the HbA1c included mean
random serum glucose concentration (Po0.0001), age
(Po0.0001), erythropoietin dose (P¼ 0.012), number of
years on dialysis (P¼ 0.008), and diabetes duration
(P¼ 0.04). A similar model was constructed for % GA;
where significant values included mean random serum
glucose concentration (Po0.0001), age (Po0.0001), body
mass index (Po0.0001), and diabetes duration (P¼ 0.046).
DISCUSSION
Accurate determination of glycemic control is of paramount
importance in the diabetic population, as improved glycemic
control reduces micro- and macrovascular complications in
patients with type 1 and type 2 diabetes mellitus.9,10 Diabetic
dialysis patients are especially at high risk, as more than 23%
of incident diabetic dialysis patients in the United States will
succumb to cardiovascular and infectious complications
during their first year of renal replacement therapy and only
31% survive 5 years.2 Glycemic control improves survival in
patients on hemodialysis.11,12 Moreover, mild degrees of
hyperglycemia in nondiabetic dialysis populations have been
associated with reduced survival.13 An accurate assessment of
glycemic control in the dialysis population is therefore
critical, to improve outcomes and survival.
HbA1c has been a cornerstone in the evaluation of dialyzed
and nondialyzed diabetic patients. This measurement relies
on a relatively stable RBC survival, a characteristic typical of
the general population but not patients on hemodialysis.
During hemodialysis, the uremic environment, blood loss
during treatments, and frequent phlebotomy all contribute to
decreased RBC lifespan. Shortened RBC survival and red cell
transfusions are likely to lower the HbA1c, potentially making
it unreliable in assessing glycemic control. Indeed, in a large
study that ultimately detected a relationship between HbA1c
and dialytic survival, a significant relationship was not
detected until controlling for differences in the hemoglobin
concentration.12 The current investigation provides further
insights into factors that are associated with HbA1c values.
This report demonstrates that HbA1c, relative to % GA,
significantly underestimates glycemic control in diabetic
dialysis patients. In those with ESRD, lower HbA1c values
were also associated with lower hemoglobin concentration
and higher doses of erythropoietin. The treatment of chronic
kidney disease-associated anemia was revolutionized with
erythropoietin, a hormone that stimulates RBC formation
and slightly increases RBC survival.14,15 Dialysis patients with
lower hemoglobin concentrations and receiving high doses of
erythropoietin may have reduced RBC survival and shorter
hemoglobin lifespan that is not overcome with high doses of
erythropoietin. In contrast, % GA was not associated with
hemoglobin, serum albumin concentration, or erythropoietin
Table 3 | Results of multivariate analyses in diabetic subjects with ESRD
Variable HbA1c full model P-value HbA1c reduced model P-value % GA full model P-value % GA reduced model P-value
Age o0.0001 o0.0001 0.004 0.006
Ethnicity 0.12 0.08 0.028 0.021
Gender 0.11 0.09 0.001 0.002
Diabetes duration 0.096 0.051 0.006 0.001
Serum glucose o0.0001 o0.0001 o0.0001 o0.0001
ACEi/ARB 0.91 NS 0.43 NS
Smoking status 0.57 NS 0.088 NS
Albumin 0.67 NS 0.81 NS
Dialysis status 0.0002 o0.0001 0.75 0.83
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DM, diabetes mellitus; ESRD, end-stage renal disease; HbA1c, hemoglobin A1c; NS, not
significant; % GA, percentage of glycated albumin.
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Figure 3 | Impact of hemoglobin concentration and EPO dose on
HbA1c in diabetic ESRD. Relationship between HbA1c and weekly
erythropoietin dose (upper panel); and hemoglobin concentration
(lower panel) in diabetic subjects on hemodialysis.
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dose. As previously noted, % GA is associated with body
mass index, a factor for which adjustment can be
performed.16,17 Therefore, % GA may be a more robust
indicator of long-term glycemia than HbA1c in hemodialysis
patients.
A relative reduction in HbA1c among Japanese patients
with type 2 diabetes on hemodialysis was reported by Inaba
et al.8 The % GA/HbA1c ratio was 2.93 in those with normal
renal function and 3.81 in dialysis patients (Po0.001). In the
current study, the % GA/HbA1c ratio was 2.07 in American
diabetics without severe nephropathy and 2.71 in dialysis
patients. Thus, the relationship between % GA/HbA1c ratios
in diabetic patients with kidney failure, relative to those
without, was nearly identical in Japanese (3.81/2.93¼ 1.30)
and Americans (2.72/2.07¼ 1.31), revealing that a uniform
bias is introduced by lower HbA1c measurements in those on
hemodialysis.
The absolute GA value (and % GA) in our study differed
from those in the Japanese report due to use of different
serum albumin assays.8 Inaba et al. used a new and improved
method for albumin measurement.18 However, the reported
difference between the older bromocresol purple methods
and the bromocresol green (BCG) in patients undergoing
hemodialysis is albumin concentration (BCG in
g l1)¼ 5.5þ albumin concentration (bromocresol purple
in g l1); an approximately 20% lower value compared with
the BCG method.19 On the basis of this, the albumin
concentrations in our study should be approximately 20%
higher than if the new bromocresol purple method were
used. Adjusting our % GA values upward by 20% coincides
well with the Japanese results. For example, the % GA/HbA1c
was 2.72 and 2.07 in the US participants on hemodialysis and
without nephropathy, respectively; translating to ‘corrected’
values of 3.26 (2.72*1.2) and 2.48 (2.07*1.2) with the new
bromocresol purple method. In fact, these estimates
approach the Japanese % GA/HbA1c values, 3.81 in
hemodialysis patients and 2.93 in nonnephropathy partici-
pants. The large number of African Americans in our study,
some likely carriers of hemoglobin S, hemoglobin C, and
thalassemia (potentially shortening RBC survival during the
stress of hemodialysis) may also be associated with slightly
different results in our report. Another way to look at these
data is through the relative reference ranges, which differ
because of the differences in the type of albumin assay. Our
US normal % GA range was 11.6%±1.6. When multiplied by
20%, the mean % GA becomes 13.9% and coincides well with
the reference interval of 12.3–16.9% GA in the report of the
Committee on Standardization of Laboratory Testing Related
to Diabetes Mellitus of the Japan Diabetes Society: Determi-
nation of the Reference Intervals of Hemoglobin A1c (IFCC)
and Glycoalbumin in the Japanese Population. According to
the recent American College of Pathology surveys, approxi-
mately 50% of clinical laboratories in the United States utilize
the BCG method for albumin analysis.
As in the present report, the Japanese study detected
positive associations between hemoglobin concentration and
HbA1c. However, Inaba et al.
8 reported that higher serum
albumin concentrations were associated with a lower % GA.
We did not find such a relationship. Inaba et al.8 also reported
that pre- and postdialysis GA results were equivalent,
excluding falsely high GA determinations due to uremic toxin
accumulation. Finally, it should be mentioned that the dose
of erythropoietin in American dialysis patients far exceeded
that administered to Japanese dialysis patients. A relationship
between higher erythropoietin dose and lower hemoglobin
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Figure 4 | Impact of hemoglobin concentration, serum albumin
and EPO dose on glycated albumin in diabetic ESRD. Relationship
between % GA and serum albumin concentration (upper panel);
weekly erythropoietin dose (middle panel); and hemoglobin
concentration (lower panel) in diabetic subjects on hemodialysis.
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concentration is well documented in the US dialysis
population.
Potential weaknesses in this study include use of random
(not necessarily fasting) recent blood glucose measures in
participants on dialysis and those without nephropathy, the
small number of African American diabetic nonnephropathy
participants, and marked ethnic differences among the
dialysis patients and those without nephropathy. Fasting
blood glucose measurements could not readily be obtained,
as patients on the afternoon hemodialysis shift are unable to
report fasting, and those on the morning shift are typically
away from home for periods exceeding 6 h and are not
permitted to eat or drink during hemodialysis. The marked
ethnic differences between ESRD participants and non-
nephropathy participants reflected the increased risk for
nephropathy in African Americans. The relationship between
% GA and HbA1c was consistent in the African American
nondialysis cohort, as well as in the non-African American
(predominantly Caucasian) groups (Table 2). However,
ethnic differences in this relationship were observed among
subjects on hemodialysis. Finally, these results are predomi-
nantly from subjects with type 2 diabetes. Although the
results may be generalizable to those with type 1 diabetes
mellitus, this will require further study.
HbA1c has long been the assay of choice for determining
long-term glycemic control among dialysis patients; there-
fore, it is crucial that the limitations of this assay be
appreciated. Blood glucose tends to decline in diabetic
patients with progressive nephropathy due to malnutrition,
increased half-life of insulin, and reduced rate of gluconeo-
genesis. However, the elevated % GA/HbA1c ratio in diabetic
dialysis patients, relative to diabetic subjects without
nephropathy, strongly suggests that HbA1c was falsely
reduced in diabetic subjects on hemodialysis, an effect likely
due to shortened RBC survival.
A consistent relationship between the % GA and HbA1c in
two independent studies demonstrates that long-term
glycemic control in diabetic hemodialysis patients vary based
upon the assay used. These reports evaluated more than 1200
diabetic subjects from three ethnic groups. Together, they
support % GA as a more accurate test of long-term glycemic
control among diabetic hemodialysis patients. It will be
important to determine the accuracy of long-term glycemic
assays in diabetic subjects with less severe degrees of renal
impairment (stages III, IV, and V chronic kidney disease) and
whether % GA is an accurate predictor of morbidity and
mortality in diabetic subjects on hemodialysis, as in
nondialysis populations.20,21
MATERIALS AND METHODS
Patients
Subjects with a clinical diagnosis of type 1 or type 2 diabetes
mellitus were invited to participate; all received oral hypoglycemic
agents, insulin, or both (one dialysis patient had diabetes
medications withheld due to recurrent hypoglycemia). Patients
with ESRD received hemodialysis treatments and intravenous
erythropoietin at Wake Forest University School of Medicine
(WFUSM) owned and operated outpatient dialysis units in north-
western North Carolina. Subjects without kidney disease were
recruited from WFUSM primary care clinics and denied prior
kidney disease, nephrology care, and receipt of erythropoietin or
dialysis. Patients on hemodialysis were intentionally over sampled,
due to the previously reported disparity between assays of glycemia
in this population.
Participants provided demographic and medical information,
10 ml of blood, and access to existing laboratory results. Blood was
drawn from the dialyzer circuit in subjects with ESRD, prior to
initiation of dialysis or administration of anticoagulants. Blood
samples were then divided with 5 ml sent for HbA1c and 5 ml
centrifuged with the serum frozen at 801C for future measurement
of GA. All subjects provided written informed consent and the study
was approved by the Institutional Review Board at the WFUSM.
Information collected from participants included demographic
data, height, weight (dry weight in hemodialysis patients), duration
of diabetes, smoking status, use of angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers, and random serum
glucose concentrations performed in CLIA-certified laboratories. In
subjects on dialysis, the minimum and maximum doses of
erythropoietin in units over the preceding 3 months were recorded.
The dialysis dose (single pool Kt/V; urea reduction ratio), transferrin
saturation, ferritin, blood urea nitrogen, serum creatinine, and
aspartate aminotransferase concentrations were recorded from the
current monthly dialysis lab report.
GA and HbA1c assays
Serum albumin concentrations were measured using the BCG assay,
calibrated to the College of American Pathologists. Glycated
albumin was measured using the LUCICA GA-L kit (Asahi Kasei
Pharma Corporation, Tokyo, Japan) on frozen serum samples
(freezer time at 801C ranged from 2 to 68 days). This kit uses an
enzymatic method that converts GA to glycated amino acids. The
amino acids are then oxidized with the formation of hydrogen
peroxide, which is coupled to a dye yielding a purple–blue color. The
GA analysis was performed on the automated ‘ADVIA 1650’
instrument (Siemens Medical Solutions Diagnostics, Tarrytown,
NY, USA). The normal % GA range (11.6±1.6%) was determined
in nondiabetic American volunteers without kidney disease.
HbA1c was analyzed within 24 h of collection (refrigerated
if not immediately assayed) on a cation exchange column
chromatograph using an automated high-pressure liquid chroma-
tography instrument (Variant II Turbo; Bio-Rad Laboratories,
Hercules, CA, USA).
Statistical analyses
The % GA was calculated as (glycated albumin/serum albu-
min*100). An average of the minimum and maximum erythro-
poietin doses over the 3 months immediately preceding the study
was determined. Descriptive statistics, including means and
standard deviations for continuous measures and frequencies and
proportions for categorical data, were calculated. Univariate group
comparisons were performed via an independent t-test for
continuous measures or a w2 test for categorical data; hemoglobin
group differences were tested by a Wilcoxon two-sample test due to
the sparse data in controls (n¼ 10). Pearson’s correlation coefficient
(R) was used to assess the strength of the relationships between
clinical variables. Analysis of variance was used to assess the
difference in slope of the lines between study groups, and a
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multivariate analysis of variance was used to construct a full model
to determine which factors were associated with HbA1c and %
GA. Reduced models were created via an iterative backward stepwise
procedure, until all remaining variables had a P-valuep0.05.
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